Wennerholm Ulla-Britt, Bergman Lina, Kuusela Pihla, Ljungström Elin, Möller Anna C, Hongslo Vala Cecilie, Ekelund Ann-Catrin, Liljegren Ann, Petzold Max, Sjögren Petteri, Svensson Mikael, Strandell Annika, Jacobsson Bo
Region Västra Götaland, Sahlgrenska University Hospital, Department of Obstetrics and Gynecology, Gothenburg, Sweden.
Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Front Med (Lausanne). 2023 Feb 28;10:1111315. doi: 10.3389/fmed.2023.1111315. eCollection 2023.
Preterm birth is the leading cause of childhood mortality and morbidity. We aimed to provide a comprehensive systematic review on randomized controlled trials (RCTs) on progesterone, cerclage, pessary, and acetylsalicylic acid (ASA) to prevent preterm birth in asymptomatic women with singleton pregnancies defined as risk of preterm birth and multifetal pregnancies.
Six databases (including PubMed, Embase, Medline, the Cochrane Library) were searched up to February 2022. RCTs published in English or Scandinavian languages were included through a consensus process. Abstracts and duplicates were excluded. The trials were critically appraised by pairs of reviewers. The Cochrane risk-of-bias tool was used for risk of bias assessment. Predefined outcomes including preterm birth, perinatal/neonatal/maternal mortality and morbidity, were pooled in meta-analyses using RevMan 5.4, stratified for high and low risk of bias trials. The certainty of evidence was assessed using the GRADE approach. The systematic review followed the PRISMA guideline.
The search identified 2,309 articles, of which 87 were included in the assessment: 71 original RCTs and 16 secondary publications with 23,886 women and 32,893 offspring. Conclusions were based solely on trials with low risk of bias ( = 50).Singleton pregnancies: Progesterone compared with placebo, reduced the risk of preterm birth <37 gestational weeks: 26.8% vs. 30.2% (Risk Ratio [RR] 0.82 [95% Confidence Interval [CI] 0.71 to 0.95]) (high certainty of evidence, 14 trials) thereby reducing neonatal mortality and respiratory distress syndrome. Cerclage probably reduced the risk of preterm birth <37 gestational weeks: 29.0% vs. 37.6% (RR 0.78 [95% CI 0.69 to 0.88]) (moderate certainty of evidence, four open trials). In addition, perinatal mortality may be reduced by cerclage. Pessary did not demonstrate any overall effect. ASA did not affect any outcome, but evidence was based on one underpowered study.Multifetal pregnancies: The effect of progesterone, cerclage, or pessary was minimal, if any. No study supported improved long-term outcome of the children.
Progesterone and probably also cerclage have a protective effect against preterm birth in asymptomatic women with a singleton pregnancy at risk of preterm birth. Further trials of ASA are needed. Prevention of preterm birth requires screening programs to identify women at risk of preterm birth.
[https://www.crd.york.ac.uk/prospero/], identifier [CRD42021234946].
早产是儿童死亡和发病的主要原因。我们旨在对孕酮、宫颈环扎术、子宫托和阿司匹林(ASA)预防单胎妊娠和多胎妊娠无症状妇女早产的随机对照试验(RCT)进行全面系统评价,这些妇女被定义为有早产风险。
截至2022年2月,检索了六个数据库(包括PubMed、Embase、Medline、Cochrane图书馆)。通过共识过程纳入以英语或斯堪的纳维亚语言发表的RCT。排除摘要和重复项。由成对的评审员对试验进行严格评估。使用Cochrane偏倚风险工具进行偏倚风险评估。使用RevMan 5.4对包括早产、围产期/新生儿/孕产妇死亡率和发病率在内的预定义结局进行荟萃分析,并根据偏倚风险高和低的试验进行分层。使用GRADE方法评估证据的确定性。系统评价遵循PRISMA指南。
检索到2309篇文章,其中87篇纳入评估:71项原始RCT和16篇二次发表文章,涉及23886名妇女和32893名后代。结论仅基于偏倚风险低的试验(n = 50)。单胎妊娠:与安慰剂相比,孕酮降低了<37孕周早产的风险:26.8% 对30.2%(风险比[RR] 0.82 [95%置信区间[CI] 0.71至0.95])(证据确定性高,14项试验),从而降低了新生儿死亡率和呼吸窘迫综合征。宫颈环扎术可能降低了<37孕周早产的风险:29.0% 对37.6%(RR 0.78 [95% CI 0.69至0.88])(证据确定性中等,四项开放性试验)。此外,宫颈环扎术可能降低围产期死亡率。子宫托未显示任何总体效果。ASA未影响任何结局,但证据基于一项效能不足的研究。多胎妊娠:孕酮、宫颈环扎术或子宫托的效果极小(如有)。没有研究支持改善儿童的长期结局。
孕酮以及可能宫颈环扎术对有早产风险的无症状单胎妊娠妇女预防早产有保护作用。需要进一步开展ASA试验。预防早产需要筛查项目来识别有早产风险的妇女。